Related Experiment Video
Updated: Jan 16, 2026
08:07
Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
Published on: April 5, 2024
1.4K
Shaofu Zhuyu Decoction for Treating Endometriosis: A Systematic Review and Meta-Analysis
Su-Bin Kim1, Young-Jin Yoon2,3, Soo-Hyun Sung4
1Department of Korean Medicine, School of Korean Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
Pharmaceuticals (Basel, Switzerland)
|September 27, 2025
Summary
Shaofu Zhuyu Decoction (SZD) combined with conventional medication (CM) significantly improves endometriosis treatment outcomes. This traditional Chinese herbal formula enhances efficacy, reduces pain and CA-125 levels, with comparable safety to CM alone.
Area of Science:
- Integrative Medicine
- Gynecology
- Pharmacology
Background:
- Endometriosis is a chronic gynecological condition characterized by pelvic pain and infertility.
- Shaofu Zhuyu Decoction (SZD), a traditional Chinese herbal formula, is clinically used for "blood stasis" disorders, including endometriosis.
- Existing evidence on SZD's efficacy and safety for endometriosis is fragmented, necessitating a comprehensive review.
Purpose of the Study:
- To systematically review and meta-analyze the clinical efficacy and safety of SZD combined with conventional medication (CM) for endometriosis.
- To compare the outcomes of SZD + CM versus CM alone in treating endometriosis patients.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Searched major databases (PubMed, EMBASE, CNKI, Web of Science) up to May 2024.
- Assessed risk of bias using the Risk of Bias 2.0 tool; primary outcome was total effective rate (TER), secondary outcomes included CA-125, VAS pain scores, recurrence, and adverse events.
Main Results:
- Eleven RCTs involving 1186 patients were included.
- SZD + CM significantly improved TER (OR 1.15; 95% CI: 1.09-1.22) compared to CM alone.
- Significant reductions in serum CA-125 levels (OR -1.57; 95% CI: -2.18 to -0.95) and VAS pain scores (OR -4.90; 95% CI: -6.82 to -2.98) were observed with SZD + CM. Lower recurrence rates were noted in three studies, and adverse events were mild and comparable.
Conclusions:
- SZD combined with CM demonstrates superior efficacy in improving endometriosis symptoms, biochemical markers, and pain intensity compared to CM alone.
- The combination therapy shows an acceptable safety profile.
- Further rigorous, multicenter trials are recommended to validate these findings and support the integration of SZD into global endometriosis management.
